Continued statin therapy could improve the outcome after spontaneous intracerebral hemorrhage

被引:50
作者
Tapia-Perez, J. H. [1 ]
Rupa, R. [1 ]
Zilke, R. [1 ]
Gehring, S. [1 ]
Voellger, B. [1 ]
Schneider, T. [1 ]
机构
[1] Otto Von Guericke Univ, Klin Neurochirurg, D-39120 Magdeburg, Germany
关键词
Intracerebral hemorrhage; Immunomodulation; Pleiotropic effect; Statins; ANEURYSMAL SUBARACHNOID HEMORRHAGE; HIGH-DOSE ATORVASTATIN; REDUCTASE INHIBITOR; CLINICAL-RESEARCH; STROKE; SIMVASTATIN; CORONARY; EVENTS; SAFETY; ROSUVASTATIN;
D O I
10.1007/s10143-012-0431-0
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Spontaneous intracerebral hemorrhage (ICH) often represents a devastating event despite maximal therapeutic efforts. Statins are drugs primarily used as cholesterol reducers with several pleiotropic effects that may result in neuroprotection. In this study, we assessed the continued use of statins after acute ICH. From January 2008 to October 2010, we analyzed a retrospective cohort of 178 patients with acute ICH. Patients with head injury, cerebral tumors, hemorrhage after ischemic stroke, and having a National Institute Health Stroke Scale (NIHSS) score of greater than 30 points on admission were excluded. In 29 patients, statins were continued within the first 24 h after onset of ICH and, subsequently, given daily until discharge, whereas 149 nonusers were used as controls. Inpatient mortality, NIHSS, and Glasgow Outcome Score (GOS) at discharge as well as mortality after 10 days, 3 months, and 6 months were recorded as outcomes. Additionally, changes of C-reactive protein (CRP) and white blood cell (WBC) counts, as well as aspartate transaminase and alanine transaminase levels were assessed. Except for the number of hypertensive and diabetic patients, characteristics on admission were similar between both groups. No mortality was observed in statin users, whereas 19 controls (12.7 %) died (p = 0.04) until discharge; after 10 days, 3 months, and 6 months, a similar trend was found. After 6 months, statin use was associated to lower mortality in regression models (OR = 0.32, 95 % CI = 0.11-0.95, p = 0.04). In the same way, statin use was related to NIHSS reduction (-3.53, 95 % CI = -7.59 to 0.42, p = 0.07). In mixed models, changes of WBC counts and CRP levels were associated with statin use. The hepatic enzymes were similar between groups. The continued use of statins after ICH could be associated to early neurological improvement and may reduce mortality within 6 months. Immunomodulation as a pleiotropic effect of statins may represent one of the underlying mechanisms.
引用
收藏
页码:279 / 287
页数:9
相关论文
共 48 条
[41]   Effects of acute pravastatin treatment on intensity of rescue therapy, length of inpatient stay, and 6-month outcome in patients after aneurysmal subarachnoid hemorrhage [J].
Tseng, Ming-Yuan ;
Hutchinson, Peter J. ;
Czosnyka, Marek ;
Richards, Hugh ;
Pickard, John D. ;
Kirkpatrick, Peter J. .
STROKE, 2007, 38 (05) :1545-1550
[42]   Preclinical and clinical research on inflammation after intracerebral hemorrhage [J].
Wang, Jian .
PROGRESS IN NEUROBIOLOGY, 2010, 92 (04) :463-477
[43]   Safety of high-dose atorvastatin therapy [J].
Waters, DD .
AMERICAN JOURNAL OF CARDIOLOGY, 2005, 96 (5A) :69F-75F
[44]   Statin Use Following Intracerebral Hemorrhage A Decision Analysis [J].
Westover, M. Brandon ;
Bianchi, Matt T. ;
Eckman, Mark H. ;
Greenberg, Steven M. .
ARCHIVES OF NEUROLOGY, 2011, 68 (05) :573-579
[45]   Spontaneous intracerebral hemorrhage: epidemiology and clinical presentation [J].
Woo, D ;
Broderick, JP .
NEUROSURGERY CLINICS OF NORTH AMERICA, 2002, 13 (03) :265-+
[46]   Statins and neuroprotection A prescription to move the field forward [J].
Wood, W. Gibson ;
Eckert, Gunter P. ;
Igbayboa, Urule ;
Mueller, Walter E. .
NEUROPROTECTIVE AGENTS, 2010, 1199 :69-76
[47]   TREATMENT OF ACUTE CEREBRAL-HEMORRHAGE WITH INTRAVENOUS GLYCEROL - A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED TRIAL [J].
YU, YL ;
KUMANA, CR ;
LAUDER, IJ ;
CHEUNG, YK ;
CHAN, FL ;
CHANG, CM ;
CHEUNG, RTF ;
FONG, KY .
STROKE, 1992, 23 (07) :967-971
[48]  
Zacco A, 2003, J NEUROSCI, V23, P11104